Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Deal Watch: Arbor Betting On Building Horizant Commercially As Xenoport Couldn't

Jun 06 2016

• By Lucie Ellis-Taitt and Ian Haydock

Related Content

FDA Approves Horizant For Restless Legs Syndrome, Bringing Relief To XenoPort, Revenues To GSK

Apr 07 2011

Arbor's Bid For XenoPort Likely Driven By Effort To Grow Horizant

May 23 2016

Eisai’s Lenvima Will Face Off Against Nexavar In Thyroid Cancer

Feb 13 2015

Related Companies

Arbor Pharmaceuticals, LLC

XenoPort, Inc.

Dr. Reddy's Laboratories Ltd.

Indivior plc

GSK plc

Jazz Pharmaceuticals plc

Celator Pharmaceuticals, Inc.

Vertex Pharmaceuticals Incorporated

Spero Therapeutics, Inc.

Astellas Pharma, Inc.

Baxter International Inc.

Baxalta Incorporated

Mayo Clinic

Merck KGaA

Eisai Co., Ltd.

Novartis AG

Ligand Pharmaceuticals, Inc.

Boehringer Ingelheim GmbH

Inventiva S.A.

AbbVie Inc.

Additional Topics

United States Deals BioPharmaceutical

More from United States

More from North America

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window